ASH 2024: Updates in the Treatment of CLL - Episode 12
Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients
Panelists discuss how the placement of chimeric antigen receptor (CAR) T-cell therapy in heavily pretreated chronic lymphocytic leukemia (CLL) continues to evolve with encouraging long-term TRANSCEND CLL-004 data from ASH 2024, while factors such as prior therapy responses, genetic profiles, and timing of progression help guide the sequencing decision between CAR T-cell therapy and pirtobrutinib in patients previously exposed to both covalent Bruton tyrosine kinase and BCL2 inhibitors.
Video Player is loading.
Video content above is prompted by the following:
- Moving beyond second-line therapy in relapsed/refractory (R/R) CLL where patients have been exposed to both covalent BTK and BLC2 inhibitors, we now have CAR T-cell therapy. What has your clinical experience been with CAR T-cell therapy? What are your thoughts on the updated follow-up TRANSCEND CLL-004 data from ASH 2024?
- How are you sequencing between CAR T-cell therapy and pirtobrutinib for those exposed to covalent BTK and BCL2 inhibitors?
- How do factors like time to progression, genomic profile, prior toxicities, etc influence your decision-making?
